Selected research
Industry Research
Pneumococcal Vaccine Polyvalent Industry Research Report 2026
Market perspective
The global Pneumococcal Vaccine Polyvalent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pneumococcal Vaccine Polyvalent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pneumococcal Vaccine Polyvalent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pneumococcal Vaccine Polyvalent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pneumococcal Vaccine Polyvalent include Merck & Co. and Pfizer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pneumococcal Vaccine Polyvalent market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pneumococcal Vaccine Polyvalent Market by Company
Merck & Co.
Pfizer
Pneumococcal Vaccine Polyvalent Segment by Type
Prevnar 13
Pneumovax23
Pneumococcal Vaccine Polyvalent Segment by Application
65 Years and Older
19 To 64 Years Old
18 Years and Younger
Pneumococcal Vaccine Polyvalent Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Vaccine Polyvalent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Vaccine Polyvalent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Vaccine Polyvalent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pneumococcal Vaccine Polyvalent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pneumococcal Vaccine Polyvalent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pneumococcal Vaccine Polyvalent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prevnar 13
- Pneumovax23
Applications
- 65 Years and Older
- 19 To 64 Years Old
- 18 Years and Younger
Companies covered
- Merck & Co.
- Pfizer
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pneumococcal Vaccine Polyvalent Market Size (2021-2032)
- 2.2.2 Global Pneumococcal Vaccine Polyvalent Sales (2021-2032)
- 2.2.3 Global Pneumococcal Vaccine Polyvalent Market Average Price (2021-2032)
- 2.3 Pneumococcal Vaccine Polyvalent by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Prevnar 13
- 2.3.3 Pneumovax23
- 2.4 Pneumococcal Vaccine Polyvalent by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 65 Years and Older
- 2.4.3 19 To 64 Years Old
- 2.4.4 18 Years and Younger
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pneumococcal Vaccine Polyvalent Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pneumococcal Vaccine Polyvalent Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Pneumococcal Vaccine Polyvalent Revenue of Manufacturers (2021-2026)
- 3.4 Global Pneumococcal Vaccine Polyvalent Average Price by Manufacturers (2021-2026)
- 3.5 Global Pneumococcal Vaccine Polyvalent Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pneumococcal Vaccine Polyvalent, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pneumococcal Vaccine Polyvalent, Product Type & Application
- 3.8 Global Manufacturers of Pneumococcal Vaccine Polyvalent, Established Date
- 3.9 Global Pneumococcal Vaccine Polyvalent Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck & Co.
- 4.1.1 Merck & Co. Company Information
- 4.1.2 Merck & Co. Business Overview
- 4.1.3 Merck & Co. Pneumococcal Vaccine Polyvalent Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolio
- 4.1.5 Merck & Co. Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Pneumococcal Vaccine Polyvalent Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio
- 4.2.5 Pfizer Recent Developments
5 Global Pneumococcal Vaccine Polyvalent Market Scenario by Region
- 5.1 Global Pneumococcal Vaccine Polyvalent Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021-2032
- 5.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021-2026
- 5.2.2 Global Pneumococcal Vaccine Polyvalent Sales by Region: 2027-2032
- 5.3 Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2021-2032
- 5.3.1 Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2021-2026
- 5.3.2 Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2027-2032
- 5.4 North America Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
- 5.4.1 North America Pneumococcal Vaccine Polyvalent Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
- 5.4.3 North America Pneumococcal Vaccine Polyvalent Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
- 5.5.1 Europe Pneumococcal Vaccine Polyvalent Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
- 5.5.3 Europe Pneumococcal Vaccine Polyvalent Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pneumococcal Vaccine Polyvalent Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pneumococcal Vaccine Polyvalent Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
- 5.7.1 South America Pneumococcal Vaccine Polyvalent Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
- 5.7.3 South America Pneumococcal Vaccine Polyvalent Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pneumococcal Vaccine Polyvalent Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032)
- 6.1.1 Global Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2021-2032)
- 6.2 Global Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2032)
- 6.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2021-2032)
- 6.3 Global Pneumococcal Vaccine Polyvalent Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032)
- 7.1.1 Global Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2021-2032)
- 7.2 Global Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2032)
- 7.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2021-2032)
- 7.3 Global Pneumococcal Vaccine Polyvalent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pneumococcal Vaccine Polyvalent Value Chain Analysis
- 8.1.1 Pneumococcal Vaccine Polyvalent Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pneumococcal Vaccine Polyvalent Production Mode & Process
- 8.2 Pneumococcal Vaccine Polyvalent Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pneumococcal Vaccine Polyvalent Distributors
- 8.2.3 Pneumococcal Vaccine Polyvalent Customers
9 Global Pneumococcal Vaccine Polyvalent Analyzing Market Dynamics
- 9.1 Pneumococcal Vaccine Polyvalent Industry Trends
- 9.2 Pneumococcal Vaccine Polyvalent Industry Drivers
- 9.3 Pneumococcal Vaccine Polyvalent Industry Opportunities and Challenges
- 9.4 Pneumococcal Vaccine Polyvalent Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst